首页 / 院系成果 / 成果详情页

New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer 期刊论文

编号：

5e7bd575-7c89-48d6-b09c-5614b688ba17
作者：

Luo, Guopei(罗国培)#^[1,2,3]Fan, Zhiyao^[1,2,3];Cheng, He^[1,2,3];Jin, Kaizhou(金凯舟)^[1,2,3]Guo, Meng^[1,2,3];Lu, Yu^[1,2,3];Yang, Chao^[1,2,3];Fan, Kun^[1,2,3];Huang, Qiuyi^[1,2,3];Long, Jiang(龙江)^[1,2,3]Liu, Liang(刘亮)^[1,2,3]Xu, Jin(徐近)^[1,2,3]Lu, Renquan(卢仁泉)^[4]Ni, Quanxing^[1,2,3];Warshaw, Andrew L.^[5,6];Liu, Chen(刘辰)^[1,2,3]Yu, Xianjun(虞先濬)^[1,2,3]
语种：

English
期刊：

PANCREATOLOGY ISSN：1424-3903 2018 年 18 卷 8 期 (971 - 976) ; DEC
收录：
关键词：

Biomarker CA19-9 Diagnosis Lewis antigen Pancreatic adenocarcinoma
摘要：

Background: Carbohydrate antigen 19-9 (CA19-9) is the best-validated biomarker for pancreatic cancer. The National Comprehensive Cancer Network (NCCN) guideline asserts that "CA19-9 will be undetectable in Lewis antigen-negative individuals". However, reports of CA19-9 secretion and its significance in Lewis (-) patients with pancreatic cancer have been inconsistent. This study was to examine serum CA19-9 levels in patients with pancreatic cancer according to Lewis status. Methods: Patients with pancreatic cancer (1482 cases) were retrieved from a prospectively maintained database. Patients with benign pancreatic disease (210 cases) and normal subjects (315 cases) were used as controls. Lewis genotypes were examined by fucosyltransferase 3 (FUT3) sequencing. Results: In patients with pancreatic cancer, 8.4% of subjects were Lewis (-), but only 41.9% of Lewis (-) subjects had CA19-9 values <= 2 U/mL. CA19-9 was even elevated (>37 U/mL) in 27.4% of Lewis (-) patients. The area under the receiver operating characteristic (ROC) curve for CA19-9 as a diagnostic biomarker was 0.842 in Lewis (-) patients with pancreatic cancer, which is closing to that of CA19-9 applied in all of patients with pancreatic cancer (0.898). Lewis (-) status was an independent prognostic factor for shorter survival in a multivariable analysis (hazard ratio (HR), 1.30, 95% confidence interval (CI), 1.03-1.64; P = 0.028). Conclusions: Not all Lewis (-) patients with pancreatic cancer are non-secretors of CA19-9. Contrary to general understanding, CA19-9 can retain its utility as a biomarker in these patients in spite of Lewis (-) genotype. (C) 2018 IAP and EPC. Published by Elsevier B.V. All rights reserved.
推荐引用方式
GB/T 7714：

Luo Guopei,Fan Zhiyao,Cheng He, et al. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer [J].PANCREATOLOGY,2018,18(8):971-976.
APA：

Luo Guopei,Fan Zhiyao,Cheng He,Jin Kaizhou,&Yu Xianjun.(2018).New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer .PANCREATOLOGY,18(8):971-976.
MLA：

Luo Guopei, et al. "New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer" .PANCREATOLOGY 18,8(2018):971-976.

浏览次数：6  下载次数：0

分享到：

浏览次数：6

下载次数：0

打印次数：0